Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about DYN, unsubscribe in one click. Privacy
| PDUFA Date | Drug | Indication | Type | PoA |
|---|---|---|---|---|
| 2027-01-21 | z-rostudirsen | exon 51 Duchenne muscular dystrophy | BLA | 69% |
PoA = estimated probability of approval: base rates calibrated against BioRadar's verified FDA outcomes, adjusted for application type, modality, therapy area, cash runway and problems the FDA has raised with the application, as the company has disclosed them. Not investment advice. See the full PDUFA calendar →
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Zeleciment Basivarsen | Myotonic Dystrophy Type 1 (DM1) | Phase 3 · NCT07486934 | Recruiting |
| Zeleciment Rostudirsen | Duchenne Muscular Dystrophy (DMD) | Phase 3 · NCT07608432 | Recruiting |
| DYNE-101 | Myotonic Dystrophy Type 1 (DM1) | Phase 1/2 · NCT05481879 | Active not recruiting |
| DYNE-251 | Duchenne Muscular Dystrophy (DMD) | Phase 1/2 · NCT05524883 | Active not recruiting |
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
DYN holds $1.1B in cash and short-term investments (as of Sep 30, 2026) and burns about $153.9M/quarter from operations, an estimated runway of 22.1 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 57 · Elevated
We believe that our cash, cash equivalents and marketable securities as of September 30, 2026 will enable us to fund our operating expenses, debt service obligations and capital expenditure requirements into the second quarter of 2028.10-Q, Nov 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when DYN files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc | Institution (13G, 5%+) | 30,785,801 | 16.43% | 2026-03-31 |
| JANUS HENDERSON GROUP Ltd. | Institution (13G, 5%+) | 11,997,738 | 6.40% | 2026-06-30 |
| BlackRock, Inc. | Institution (13G, 5%+) | 11,489,504 | 6.13% | 2026-06-30 |
| FMR LLC | Institution (13G, 5%+) | 11,207,000 | 5.98% | 2026-06-30 |
| Wellington Management Group LLP | Institution (13G, 5%+) | 10,579,924 | 5.65% | 2026-09-30 |
| Dirk Kersten Director · +35,152 options |
Insider | 3,586,796 | 1.91% | 2026-07-27 |
| John Cox CEO & President, Director |
Insider | 423,994 | 0.23% | 2026-11-13 |
| Douglas Kerr Head of R&D and CMO · +12,000 options |
Insider | 167,960 | 0.09% | 2026-11-13 |
| Johanna Friedl-Naderer Chief Commercial Officer |
Insider | 152,666 | 0.08% | 2026-11-13 |
| Erick Lucera Chief Financial Officer |
Insider | 117,775 | 0.06% | 2026-11-13 |
| Brian S Posner Director · +35,152 options |
Insider | 27,000 | 0.01% | 2026-10-02 |
| Jason P Rhodes Director · +35,152 options |
Insider | 2,962 | 0.00% | 2026-08-13 |
Share count 187,386,963 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for DYN and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →